Back to funds
View filing
venBio Partners LLC
hedge fundUpdated 27 days agoManaged by Venbio Partners Llc • Latest filing Q2 2026
Portfolio value
$519.4M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
6.8%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $180.4M |
| Q2 2023 | $276.3M |
| Q3 2023 | $352.7M |
| Q4 2023 | $667.2M |
| Q1 2024 | $281.9M |
| Q2 2024 | $231.5M |
| Q3 2024 | $194.3M |
| Q4 2024 | $170.7M |
| Q1 2025 | $123.6M |
| Q2 2025 | $114.8M |
| Q3 2025 | $176.4M |
| Q4 2025 | $216.3M |
| Q1 2026 | $280.6M |
| Q2 2026 | $519.4M |
Top holdings
7 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | P PHVS PHARVARIS N V | $160.6M | 4.64M | 30.92% | — |
| 2 | P PBLS PARABILIS MEDICINES INC | $144.1M | 5.27M | 27.75% | — |
| 3 | A ALMS ALUMIS INC | $127.4M | 4.53M | 24.53% | — |
| 4 | A ACHV ACHIEVE LIFE SCIENCE INC | $38.6M | 5.91M | 7.44% | — |
| 5 | A ALXO ALX ONCOLOGY HLDGS INC | $26.7M | 12.88M | 5.14% | — |
| 6 | H HRMY HARMONY BIOSCIENCES HLDGS IN | $17.2M | 472.2K | 3.31% | — |
| 7 | L LYEL LYELL IMMUNOPHARMA INC | $4.7M | 337.7K | 0.91% | — |